By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697




Merck & Co.  Antifungals

Company News
SCYNEXIS, Inc. (SCYX) Announces Sale Of Cyclophilin Inhibitor Assets To Cypralis Limited 7/13/2016 8:12:34 AM
SCYNEXIS, Inc. (SCYX) To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference 7/6/2016 8:00:07 AM
SCYNEXIS, Inc. (SCYX) Initiates Enrollment Of The Phase II Study Of SCY-078 In Vulvovaginal Candidiasis 12/2/2015 7:46:07 AM
SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results And Provides Company Update 11/13/2015 9:17:59 AM
SCYNEXIS, Inc. (SCYX) Announces Initiation Of Phase I Clinical Trial Evaluating Intravenous Formulation Of SCY-078 11/12/2015 7:10:58 AM
SCYNEXIS, Inc. (SCYX) Appoints Eric Francois as Chief Financial Officer 11/3/2015 8:36:49 AM
SCYNEXIS, Inc. (SCYX) Appoints Rajeshwar Motheram As Vice President, Pharmaceutical Development 10/8/2015 7:26:00 AM
SCYNEXIS, Inc. (SCYX) Announces Board Of Directors Transitions 9/29/2015 7:00:12 AM
SCYNEXIS, Inc. (SCYX) Presents Data Supporting The Potential Clinical Utility Of Antifungal Drug Candidate At ICAAC/ICC 2015 9/21/2015 8:06:47 AM
SCYNEXIS, Inc. (SCYX) To Present Data At ICAAC/ICC 2015 For Novel Antifungal Drug Candidate 9/10/2015 11:04:01 AM